These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25252970)

  • 1. Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?
    Pullenayegum EM; Perampaladas K; Gaebel K; Doble B; Xie F
    Eur J Health Econ; 2015 Nov; 16(8):847-55. PubMed ID: 25252970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM; Chan KK; Xie F
    Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In search of a 'pan-European value set'; application for EQ-5D-3L.
    Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
    BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states.
    Luo N; Wang P; Thumboo J; Lim YW; Vrijhoef HJ
    Pharmacoeconomics; 2014 May; 32(5):495-507. PubMed ID: 24519603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
    Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
    Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selecting Health States for EQ-5D-3L Valuation Studies: Statistical Considerations Matter.
    Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
    Value Health; 2018 Apr; 21(4):456-461. PubMed ID: 29680103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuing EQ-5D health states for Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
    Qual Life Res; 2015 Jul; 24(7):1785-93. PubMed ID: 25543271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size.
    Chan KKW; Xie F; Willan AR; Pullenayegum EM
    Med Decis Making; 2018 Jan; 38(1):26-33. PubMed ID: 28823185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
    Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
    MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
    [No Abstract]   [Full Text] [Related]  

  • 16. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist.
    Xie F; Gaebel K; Perampaladas K; Doble B; Pullenayegum E
    Med Decis Making; 2014 Jan; 34(1):8-20. PubMed ID: 23525701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chinese time trade-off values for EQ-5D health states.
    Liu GG; Wu H; Li M; Gao C; Luo N
    Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Uncertainty in EQ-5D Value Sets: The Role of Spatial Correlation.
    Shams S; Pullenayegum E
    Med Decis Making; 2019 Feb; 39(2):91-99. PubMed ID: 30678526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set.
    Thomas S; Johnson JA; Xie F
    Qual Life Res; 2020 Nov; 29(11):3109-3118. PubMed ID: 32705459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.